[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335284-105":59,"doc-detail-335284-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","hypoxia-responsive-prodrug-of-atr-inhibitor-azd6738-selectively-eradicates-treatment-resistant-cancer-cells","Hypoxia-Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment-Resistant Cancer Cells","","Targeted cancer therapy depends on improving drug specificity while limiting damage to healthy tissues. ATR inhibitors show clinical promise, yet normal-tissue toxicities threaten their usefulness. The study reports ICT10336, a hypoxia-responsive prodrug of the ATR inhibitor AZD6738 that is activated and releases AZD6738 only under hypoxic conditions in vitro. Hypoxia-selective release suppresses ATR activation, blocks HIF1a-mediated adaptation, and induces selective cell death in 2D and 3D cancer models. In normal tissues, ICT10336 is metabolically stable and less toxic than AZD6738, with superior 3D tumor penetration that eradicates hypoxic-core cells, enhancing the therapeutic index.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hypoxia-responsive-prodrug-of-atr-inhibitor-azd6738-selectively-eradicates-treatment-resistant-cancer-cells/335284/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hypoxia-responsive-prodrug-of-atr-inhibitor-azd6738-selectively-eradicates-treatment-resistant-cancer-cells/335284.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address with ATR inhibitors?","Question",{"text":112,"@type":113},"ATR inhibitors have promising clinical potential, but normal-tissue toxicities can compromise their utility, motivating a more targeted delivery approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ICT10336 release AZD6738?",{"text":117,"@type":113},"ICT10336 is hypoxia-activated and selectively releases AZD6738 only under hypoxic conditions, demonstrated in vitro.",{"name":119,"@type":110,"acceptedAnswer":120},"What effects does hypoxia-selective AZD6738 release have on cancer cells?",{"text":121,"@type":113},"It inhibits ATR activation, disrupts HIF1a-mediated adaptation, and selectively induces cell death in 2D and 3D cancer models, including hypoxic-core eradication.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335284,1790881273,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nHypoxia-Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment-Resistant Cancer Cells  \nFrancis M. Barnieh,* Goreti Ribeiro Morais, Paul M. Loadman, Robert A. Falconer, and Sherif F. El-Khamisy  \nTargeted therapy remains the future of anti-cancer drug development, owing to the lack of speciﬁcity of current treatments which lead to damage in healthy normal tissues. ATR inhibitors have in recent times demonstrated promising clinical potential, and are currently being evaluated in the clinic. However, despite the considerable optimism for clinical success of these inhibitors, reports of associated normal tissues toxicities remain a concern and can compromise their utility. Here, ICT10336 is reported, a newly developed hypoxia-responsive prodrug of ATR inhibitor, AZD6738, which is  \nhypoxia-activated and speciﬁcally releases AZD6738 only in hypoxic conditions, in vitro. This hypoxia-selective release of AZD6738 inhibited ATR activation (T1989 and S428 phosphorylation) and subsequently abrogated HIF1a-mediated adaptation of hypoxic cancers cells, thus selectively inducing cell death in 2D and 3D cancer models. Importantly, in normal tissues, ICT10336 is demonstrated to be metabolically stable and less toxic to normal cells than its active parent agent, AZD6738. In addition, ICT10336 exhibited a superior and eﬃcient multicellular penetration ability in 3D tumor models, and selectively eradicated cells at the hypoxic core compared to AZD6738. In summary, the preclinical data demonstrate a new strategy of tumor-targeted delivery of ATR inhibitors with signiﬁcant potential of enhancing the therapeutic index.  \n1. Introduction  \nTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer accounting for 15–25% of all breast cancers, and 24% of newly diagnosed cases. [1,2] Clinical TNBCs lack the expression of oestrogen (ER), progesterone (PR), and HER2 receptors, which means patients are not suitable for either hormone or anti-HER- 2 therapy. Compared to other subtypes of breast cancer, TNBC patients have worse clinical outcomes after treatment (usually neoadjuvant chemotherapy) with higher recurrence rates. [3,4] Thus, there is a current unmet need for a better treatment options for patients. With that said, recent advances in DNA damage repair (DDR) inhibitors in TNBC treatment hold signiﬁcant promise. [5] The DDR machinery comprises the mechanisms through which DNA damage is detected and repaired to maintain genomic stability and integrity. This is critical to the survival of cells, but more importantly to cancer cells. [6] Loss or defective DDR components area common feature with TNBC, which  \nF. M. Barnieh, G. R. Morais, P. M. Loadman, R. A. Falconer,  \nS. F. El-Khamisy  \nInstitute of Cancer Therapeutics Faculty of Life Sciences University of Bradford  \nRichmond Road, Bradford BD7 1DP, United Kingdom  \nE-mail: [f.mprahbarnieh1@bradford.ac.uk](f.mprahbarnieh1@bradford.ac.uk)  \nS. F. El-Khamisy  \nSchool of Biosciences, the Healthy Lifespan Institute and the Institute of Neuroscience  \nUniversity of Sheﬃeld  \nSheﬃeldS10 2TN, United Kingdom  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202403831](https://doi.org/10.1002/advs.202403831)[ ](https://doi.org/10.1002/advs.202403831)© 2024 The Author(s). Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202403831  \noften leads to a greater reliance of cancer cells on compensatory residual DDR factors for survival. [7–9] Consequently, DDR mechanisms have been of notable interest to the treatment ofTNBC with inhibitors of DDR key players ATR (Ataxia Telangiectasia Mutated and Rad-3 Related prot","cbCaig1dayl1c53l","https://ap.wps.com/l/cbCaig1dayl1c53l","pdf",14612880,"English","# Introduction\n## Triple-negative breast cancer and unmet therapeutic need\n## DNA damage repair dependence and ATR as a target\n## AZD6738 clinical candidate and toxicity concerns\n## Rationale for tumor-targeted ATR inhibitor delivery\n# Hypoxia-responsive prodrug concept (ICT10336)","[{\"question\":\"What problem does the study address with ATR inhibitors?\",\"answer\":\"ATR inhibitors have promising clinical potential, but normal-tissue toxicities can compromise their utility, motivating a more targeted delivery approach.\"},{\"question\":\"How does ICT10336 release AZD6738?\",\"answer\":\"ICT10336 is hypoxia-activated and selectively releases AZD6738 only under hypoxic conditions, demonstrated in vitro.\"},{\"question\":\"What effects does hypoxia-selective AZD6738 release have on cancer cells?\",\"answer\":\"It inhibits ATR activation, disrupts HIF1a-mediated adaptation, and selectively induces cell death in 2D and 3D cancer models, including hypoxic-core eradication.\"}]","Hypoxia-Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment-Resistant Cancer Cells | PDF",1790010395]